Healthcare Industry News:  linear accelerator 

Devices Oncology

 News Release - January 27, 2009

Cancer Patients in Sweden and Estonia Receive Faster, More Precise Radiation Therapy Treatments

Uppsala University Hospital and Lund University Hospital in Sweden and Tartu University Hospital in Estonia invest in advanced radiotherapy systems from Elekta, a world leader in radiation therapy and radiosurgery treatment solutions.

Stockholm, Sweden January 27, 2009--(HSMN NewsFeed)--Installation of the new Elekta Synergy® systems from Elekta will enable the three university hospitals to begin treating patients with Elekta VMAT (Volumetric Modulated Arc Therapy), a new treatment technology that offers shortened treatment times with the highest degree of precision.

With Elekta Synergy, hospitals in Uppsala and Tartu will for the first time offer patients Image Guided Radiation Therapy (IGRT), which enables hospital personnel to visualize the tumor at the time of treatment, while the hospital in Lund will extend its capacity for this type of targeted treatment.

The order from Tartu University Hospital will be the first Elekta linear accelerator in Estonia. Due to significant demand in the region, installation of the new equipment will commence immediately. The hospital also has the radiation treatment planning system, XiO®, from CMS Software. CMS became part of the Elekta Group in 2008.

“Three leading university hospitals ordering Elekta systems for cancer treatment in just over a month reflects very positively on our VMAT technology,” says Lennart Ward, Elekta’s Business Unit Manager for the Nordic and Baltic countries. “Elekta VMAT is unique in allowing the clinician to optimize all parameters of treatment delivery in order to maximize dose to the tumor and minimize unwanted radiation to healthy tissue.”

“We aim to be at the forefront and implement modern radiation treatment methods,” says Kristina Nilsson, senior physician and responsible for the Department of Oncology, Radiology and Clinical Immunology at Uppsala University Hospital. “We look forward to having access to Elekta’s system for Image Guided Radiation Therapy and rotational IMRT, that is, VMAT. This will enable us to provide enhanced patient care.”

Uppsala University Hospital will begin treating patients with Elekta VMAT during autumn 2009. Lund University Hospital is planning to install the system in 2010.

For additional information about Elekta VMAT, visit

For further information, please contact:

Lennart Ward, Elekta’s Business Unit Manager for the Nordic and Baltic countries
Telephone: +46 (0)8 587 255 43, e-mail:

Lena Schattauer, Investor Relations, Elekta AB
Telephone: +46 (0)8 587 257 22, +46 (0)70 595 51 00, e-mail:

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated state of the art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives, making the future possible today.

Today, Elekta solutions in oncology and neurosurgery are used in over 5,000 hospitals globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group.

Elekta employs around 2,500 employees globally. The corporate headquarter is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. For more information about Elekta, please visit

Source: Elekta

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.